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Molecular Epidemiology of Emerging Echovirus 30
Echovirus 30 (E30) is a common cause of viral men-ingitis outbreaks and upsurges reported world-
wide (1–6). In 2018, E30 circulation was high, and 
large-scale E30 meningitis-related upsurges were 
reported in Denmark, Germany, the Netherlands, 
Norway, and Sweden, compared with data collected 
during 2015–2017 (2). E30 was detected in 14.5% of 
all confi rmed enterovirus cases  (2). The virus affected 
mainly children 0–4 years of age and adults 26–45 
years of age, and 75% of cases had central nervous 
system involvement (2).
E30 is classifi ed into the Enterovirus B (EV-B) spe-
cies within the Picornaviridae family of human en-
teroviruses and is divided into 2 genogroups (GG), 
I and II (7). Most currently circulating strains are 
classifi ed as GGII (7,8). The genome (positive-sense 
single-stranded RNA) is ≈7.4 kb long and contains 5′ 
and 3′ untranslated regions (UTRs) fl anking a single 
open reading frame (ORF), encoding 4 structural pro-
teins (viral protein [VP] 0, VP2, VP3, and VP1) and 7 
nonstructural proteins (NSP; 2A, 2B, 2C, 3A, 3B [also 
known as VPg], 3C, and 3D polymerase [3Dpol]).
E30 outbreaks display a cyclic incidence pattern 
of 3–5 years (1,7,9–13). Typically, outbreaks and up-
surges are associated with rapid spread of different, 
relatively short-lived, strains defi ned by VP1 capsid 
gene sequences (1,7,8,14–16). Novel E30 variants have 
invariably undergone recombination with other EV-B 
types before their emergence. Recombination results 
in the generation of novel recombinant forms (RFs) 
that are chimaeras of E30-derived structural genes 
with NSP, 5′ UTR sequences, or both, which are de-
rived from cocirculating E30 strains or other EV-B 
types, such as E9 and E11 (10–12,14,17,18). The role 
of VP1 sequence change, recombination, and other 
factors driving phenotypic changes in virus trans-
missibility or pathogenicity, and the contributions of 
changes in population immunity, are crucial for clari-
fying the underlying causes of E30 outbreaks and up-
surges in cases (15,19–22).
We performed an in-depth analysis of the genetic 
diversity of E30 strains detected during a large-scale 
upsurge in cases in Europe during 2018. We collated 
sequences obtained by participating laboratories in 22 
countries and analyzed the epidemiologic and evolu-
tionary profi les in this molecular study.
Methods
Data Collection
An invitation to participate in this study was sent on 
November 13, 2018, to co-authors of the E30–2018 study 
(2) through the European Centre for Disease Preven-
tion and Control (ECDC) Epidemic Intelligence Infor-
mation System Vaccine-Preventable Diseases platform 
(https://www.ecdc.europa.eu/en/publications-data/
epidemic-intelligence-information-system-epis), and to 
members of the European Non-Polio Enterovirus Net-
work (ENPEN; https://www.escv.eu/enpen). We 
requested pseudonymized data from 2016–2018 with 
sample identifi er, sampling date, specimen type, and 
sequence in FASTA be sent to ECDC secure fi le trans-
fer protocol server by January 7, 2019. We also collected 
optional data, such as patient age, clinical presentation, 
whether they were hospitalized, and infection outcome. 
We excluded submissions without virus sequence data 
(Appendix Figure 1, https://wwwnc.cdc.gov/EID/
article/27/6/20-3096-App1.pdf).
Sequence Data Collection
We requested that the FASTA sequence data contain 
the VP1 gene and collected 1,784 records (Appendix 
Figure 1). Sequences were obtained from enterovirus-
positive samples by using 5′ UTR PCR (23) and typed 
within the VP1 gene by using Sanger sequencing 
(2,24). We excluded sequences with indicators of poor 
sequence quality, such as >2 ambiguous or undefi ned 
bases, in-frame stop codons, identical to reference 
E30 strains; sequences of the wrong type, such as 
E3; or sequences shorter than 200 basepairs or span-
ning a non-VP1 region. In total, we had 1,407 study 
sequences that comprised 2 nonoverlapping regions, 
1,262 sequences from region 1 (nt positions 2543–
2902, according to the prototype E30 strain Bastianni, 
GenBank accession no. AF311938) and 145 sequences 
from region 2 (nt positions 2916–3428). Of these, 1,329 
sequences were collected during 2016–2018 and 78 
during 2010–2015. We used the 2010–2015 sequences 
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In 2018, an upsurge in echovirus 30 (E30) infections was 
reported in Europe. We conducted a large-scale epi-
demiologic and evolutionary study of 1,329 E30 strains 
collected in 22 countries in Europe during 2016–2018. 
Most E30 cases aff ected persons 0–4 years of age 
(29%) and 25–34 years of age (27%). Sequences were 
divided into 6 genetic clades (G1–G6). Most (53%) se-
quences belonged to G1, followed by G6 (23%), G2 
(17%), G4 (4%), G3 (0.3%), and G5 (0.2%). Each clade 
encompassed unique individual recombinant forms; G1 
and G4 displayed >2 unique recombinant forms. Rapid 
turnover of new clades and recombinant forms occurred 
over time. Clades G1 and G6 dominated in 2018, sug-
gesting the E30 upsurge was caused by emergence of 
2 distinct clades circulating in Europe. Investigation into 
the mechanisms behind the rapid turnover of E30 is cru-
cial for clarifying the epidemiology and evolution of these 
enterovirus infections.
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for phylogenetic reconstruction but excluded these 
from further data analysis (Appendix Figure 1). 
For additional analysis of the 3D polymerase 
(3Dpol) region, we randomly selected records from 
each clade to ensure fair distribution of sequence 
data. We asked participants to send either extracted 
RNA in a QIAGEN (https://www.qiagen.com) spin 
column at room temperature for next-generation se-
quencing (NGS) or to conduct 3Dpol sequencing of 
the 549 nucleotides, as previously described (17).
Epidemiologic and Statistical Analyses
We descriptively analyzed clinical symptoms and age. 
Patients were stratified into the following age groups: 
<3 months, 3–23 months, 2–5 years, 6–15 years, 16–25 
years, 26–45 years, 46–65 years, and >65 years. Crude 
odds ratios with 95% CI were used to express magni-
tude of association between continuous or categorical 
variables in multivariate logistic regression.
Next-Generation Sequencing
Stool suspensions and CSF samples were processed to 
remove as much nonviral material as possible by us-
ing centrifugation, filtration, and endonuclease treat-
ment. RNA was extracted by using the MagNAPure 
96 (Roche Diagnostics, https://www.roche.com) au-
tomated extraction kit or QIAGEN filters and eluted 
in 50 µL of elution buffer (Appendix).
Complementary DNA (cDNA) and double 
stranded DNA (dsDNA) were generated and pu-
rified (Appendix). For tagmentation and library 
preparation, the Nextera XT DNA Library Prepa-
ration Kit (Ilumina, https://www.illumina.com) 
was used according to the manufacturer’s instruc-
tions. Runs were performed on the Nextseq (Ilumi-
na). Raw data were processed by using Jovian (D. 
Schmitz et al., unpub. data, https://github.com/
DennisSchmitz/Jovian) (Appendix). 
Nucleotide Sequences and Phylogenetic Analysis
We conducted VP1 phylogenetic reconstruction 
with the 1,407 study sequences and 324 sequences 
extracted from Genbank. We selected region 1 for 
clade analysis because it is more commonly used for 
enterovirus typing (24). We performed analysis of 
region 2 sequences based on sequence clustering, in 
which both region 1 and 2 were available, such as full-
length sequences or sequences spanning the entire 
VP1 gene. Sequencing of the 540 nt 3Dpol gene, po-
sitions 5825–6364, also was provided for 12 samples 
with region 1 sequences (Appendix Figure 1). Sanger 
sequencing indicated that samples did not display 
double infection and that VP1 and 3Dpol were from 
1 virus. Complete genomes (≈7.3 kb) were generated 
for 48 sequences by using NGS. To compare 3Dpol 
groupings within EV species B, we downloaded all 
sequences available from GenBank as of October 18, 
2019, that were >70% complete between positions 
5825–6364 with <6 ambiguous base positions and <6 
undetermined bases and without stop codons. We 
aligned the downloaded sequences with complete ge-
nomes or 3Dpol sequences from our study.
We aligned data by using sequence editor SSE 
version 1.3 (http://www.virus-evolution.org). We 
generated maximum-likelihood and neighbor-joining 
trees for VP1 and 3Dpol regions by using MEGA ver-
sion 7 (https://www.megasoftware.net) with the op-
timal model (general time reversible plus invariant 
sites plus gamma distribution for rates over sites) and 
100 bootstraps (25). We analyzed the species B dataset 
with neighbor-joining and maximum composite like-
lihood distances.
Nextstrain VP1 Phylodynamic Analysis
The dataset used for Nextstrain phylodynamic 
analysis comprised 1,285 sequences; 1,215 study se-
quences (region 1) and 70 complete VP1 sequences 
extracted from GenBank (Appendix Figure 1). We 
excluded sequences shorter than 250 bp, sequences 
from samples collected before 1958, and sequences 
deemed as outliers during phylogenetic reconstruc-
tion. We deemed these outliers recombinants with 
possible recombination breakpoints within the se-
quence fragment used made phylogenetic recon-
struction impossible.
We aligned sequences by using MAFFT (26). We 
inferred a phylogenetic tree by using IQ-TREE (27) and 
generated time-resolved trees by using TreeTime (28) 
by estimating the mutation rate. When available, we 
attached to sequences data on country, sample type, 
E30 clade, age groups, and clinical data, such as wheth-
er patients were hospitalized and their symptoms. We 
provided the resulting Nextstrain build for viewing 
(https://nextstrain.org/community/enterovirus-
phylo/echo30-2019/vp1).
Nextstrain VP1:3Dpol Tanglegram Phylodynamics
We used a dataset of 110 sequences to conduct 3Dpol 
analysis, including 48 complete genome sequences 
and 12 3Dpol sequences generated in this study and 
50 sequences extracted from GenBank (Appendix Fig-
ure 1). We aligned 3Dpol sequences to the E30 refer-
ence sequence (GenBank accession no. MK238483) 
and inferred phylogenetic and time-resolved trees 
as we did for VP1, but we used a fixed clock rate 
of 4 × 10−3 substitutions/site/year during the time- 
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resolved tree reconstruction. We provided the resulting 
Nextstrain tanglegram build for viewing (https://
nextstrain.org/community/enterovirus-phylo/echo30-
2019/3D:community/enterovirus-phylo/echo30-2019/
vp1) and the codes for both VP1 and 3Dpol analyses 
(https://github.com/enterovirus-phylo/echo30-2019).
Genbank and ENA Accession Numbers
We deposited VP1 and complete genome sequences in 
GenBank under accession nos. KC309427–37, KY986976–
7033, MK251835–6, MK372854–80, MK507733–7, 
MK814991–6288, and MK895104–9 and 3Dpol sequenc-
es under accession nos. MN395293–303. We deposited 
NGS fastq reads in European Nucleotide Archive data-
base under accession nos. SAM17101211–58.
Results
Molecular Epidemiology and Demographics
During 2016–2018, a total of 1,329 E30 records rep-
resenting 1,292 cases that fulfilled the study criteria 
were submitted from 22 countries (Table 1; Appendix 
Figure 1). During those 3 years, the total number of 
E30 cases steadily increased (Table 1). The numbers 
varied per country per year, and we noted a clear up-
surge in 2018 in several, but not all, countries (Table 
1; Figure 1). Of the 1,329 records analyzed, 443 (33%) 
were from the United Kingdom; the Netherlands sub-
mitted 198 (15%) and Spain 162 (12%) records. Other 
countries submitted from 1 (<1%) to 117 (9%) records. 
Specimen type was reported for 1,312 (98.7%) records. 
Most (70%; 924/1,312) samples were cerebrospinal 
fluid specimens, but other specimen types included 
269 (21%) from feces specimens, 102 (8%) from respi-
ratory, and 17 (1%) from blood. During the study pe-
riod, E30 records were submitted more frequently in 
summer months; 18.4% (n = 244) were submitted in 
June, 17.6% in July (n = 234), and 11.7% in August (n 
= 155) (Figure 2).
Age was available for 1,080 (83.6%) cases and 
ranged from 0 to 73 years with a mean age of 18.7 
years. Children <5 years of age (n = 360, 33.3%) and 
adults 26–45 years of age (n = 409, 37.9%) were most 
affected (Table 2). Infants <3 months of age also were 
heavily affected (n = 223 cases, 20.6%) (Table 2).
Clinical information was available for 734 (56.8%) 
E30 cases, of which 380 cases had unknown symp-
tomology. For most (28.7%, n = 211) cases, the re-
corded signs and symptoms suggested meningitis. 
Symptoms of acute flaccid paralysis were reported in 
1 case, encephalitis in 3 cases, and meningoenceph-
alitis in 8 cases. Fever, either as sole symptom or in 
combination with other signs and symptoms, was 
recorded in only 52 (7.1%) cases. Unfortunately, not 
all records were filled in completely, and clinical data 
were absent for some samples. Other signs and symp-
toms mentioned were gastrointestinal symptoms in 
6 cases, respiratory symptoms in 6, rash in 2, other 
neurologic symptoms in 4, or other unspecified in 53 
cases; 8 cases had no symptoms. We created an in-
teractive representation of age and clinical features of 
sequences from E30 cases, which we made available 
on Nextstrain (https://nextstrain.org/community/
enterovirus-phylo/echo30-2019/vp1).
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Table 1. Number of echovirus 30 records with curated viral protein 1 sequences by country, 2016–2018* 
Country 2016, n = 325 2017, n = 493 2018, n = 511 Total, n = 1,329 
Austria 6 (1.8) 3 (0.6) 0 9 (0.7) 
Belgium 74 (22.8) 2 (0.4) 15 (2.9) 91 (6.8) 
Bulgaria 0 4 (0.8) 4 (0.8) 8 (0.6) 
Czech Republic 21 (6.5) 2 (0.4) 3 (0.6) 26 (2.0) 
Germany 11 (3.4) 4 (0.8) 12 (2.3) 27 (2.0) 
Denmark 7 (2.2) 73 (14.8) 37 (7.2) 117 (8.8) 
Spain 86 (26.5) 37 (7.5) 39 (7.6) 162 (12.2) 
Finland 1 (0.3) 0 2 (0.4) 3 (0.2) 
France 4 (1.2) 2 (0.4) 17 (3.3) 23 (1.7) 
Greece 0 3 (0.6) 8 (1.6) 11 (0.8) 
Hungary 2 (0.6) 0 0 2 (0.2) 
Ireland 13 (4.0) 46 (9.3) 23 (4.5) 82 (6.2) 
Iceland 0 0 5 (1.0) 5 (0.4) 
Italy 0 0 2 (0.4) 2 (0.2) 
Lithuania 0 0 1 (0.2) 1 (0.1) 
Luxembourg 0 4 (0.8) 4 (0.8) 8 (0.6) 
Netherlands 33 (10.2) 23 (4.7) 142 (27.8) 198 (14.9) 
Norway 4 (1.2) 28 (5.7) 34 (6.7) 66 (5.0) 
Sweden 0 0 36 (7.0) 36 (2.7) 
Slovenia 1 (0.3) 0 3 (0.6) 4 (0.3) 
Ukraine 3 (0.9) 2 (0.4) 0 5 (0.4) 
United Kingdom 59 (18.2) 260 (52.7) 124 (24.3) 443 (33.3) 
*All values expressed as no. (%). 
 
RESEARCH
Hospitalization status was available for only 
17.6% (n = 228) of cases, only 5 of which had no hospi-
talization. The low fraction of hospitalization report-
ed limited further analysis. No deaths were reported.
E30 Phylodynamics 
Among the 1,329 curated VP1 study sequences, 1,019 
(76.7%) could be subdivided into 5 distinct clades, 
G1–G5, that showed >5% sequence divergence from 
one another (Figure 3, panel A). The mean divergence 
between VP1 nucleotide sequences of G1–G5 was 
12.4%–15.2%, which translated to 2.8%–3.9% amino 
acid sequence divergence. Most (704, 53%) sequences 
belonged to G1, but 229 (17.2%) were in G2, 59 (4.4%) 
in G4, 4 (0.3%) in G3, and 2 (0.2%) in G5. These se-
quences all were assigned to GGII, 1 of 2 previously 
reported genogroups (7). The remaining 310 VP1 se-
quences formed a single clade, G6 (Figure 3), showing 
20.6% mean nucleotide differences and 8.5% amino 
acid differences from the VP1 sequences within G1–
G5 clades. G6 was sufficiently divergent from G1–G5 
(GGII). The divergence falls within the nucleotide 
divergence between GGI–GGII (19%–22%) (7), and 
G6 can be considered a third genogroup, GGIII.
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Figure 1. Geographic distribution of echovirus 30 (EV30) clades, 
Europe, 2016–2018. Clades G1–G6 were detected among 1,329 
EV30 cases from 22 countries. A) 2016; B) 2017; C) 2018. 
Molecular Epidemiology of Emerging Echovirus 30
The phylogeny showed a rapid turnover of E30 
clades over the 3 years sampled, shifting from G2 dom-
inating in 2016 to G1 and G6 dominating in 2017 and 
2018 (Figure 1). In 2016, 58.5% of strains were G2, and 
this genotype was identified in 11/22 (50%) countries. 
G2 was detected in only 8 countries in 2017 and only 
4 countries in 2018. Similarly, G4 disappeared during 
2016–2018. In 2016, both G1 and G6 were detected, G1 
in 24.6% (n = 80) of virus strains in 10 countries and G6 
in 6.5% (n = 21) of virus strains in 7 countries. Rates of 
detection for G1 and G6 steadily increased in 2017; G1 
was detected in 59.2% (n = 292) of virus strains in 12 
countries and G6 in 26.4% (n = 130) of virus strains in 
7 countries (Figure 1). During the 2018 upsurge, 64.6% 
(330) of sequences reported in 17 countries belonged 
to G1, and 33.9% (173) in 11 countries belonged to G6 
(Figure 1). These data indicate the occurrence of >2 dis-
tinct viruses dominating the upsurge in 2018 (Figure 1).
We used Nextstrain to create an interactive phy-
lodynamic tree and map to explore relationships of 
the E30 study VP1 sequences in G1–G6 (https://next-
strain.org/community/enterovirus-phylo/echo30-
2019/vp1) (Figure 3, panel B; Appendix Figure 2). We 
deemed G5 sequences as outliers and did not include 
these during phylogenetic reconstruction. Molecular 
clock analysis of the VP1 region revealed an estimated 
substitution rate of 5.12 × 10−3 substitutions/per site/
per year, comparable to rates previously determined 
for a range of enteroviruses.
Most E30 G1 viruses were detected among in-
fants <3 months of age (135/568, 24%) and in young 
adults 26–45 years of age (227/568, 40%) (Table 2). 
G2 (100/145, 68%) and G4 (29/59, 52%) were most 
frequent among children 3 months–15 years of age. 
G6 mainly was detected among children 3 months–15 
years of age (100/308, 32.5%) and in adults 26–45 
years of age (134/308, 43.5%). Only 2 cases of G3 and 
1 of G5 were reported with age information (Table 2).
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Figure 2. Monthly distribution of echovirus 30 (EV30) clades G1–G6 detected among 1,329 sequences submitted from 22 countries in 
Europe during 2016–2018. 
 
Table 2. Distribution of echovirus 30 cases in Europe by age group and clade* 
Clade 
Age range Total no. 






































12.07 (9.55–14.58) <0.001 
G3 0 0 0 0 0 2  
(0.4) 
0 0 2  
(0.2) 
35.5 (29.15–41.85) 0.142 
G4 9  
(4.0) 










0 56  
(5.2) 
16.82 (13.06–20.57) 0.269 
G5 0 0 0 0 0 1  
(0.2) 
0 0 1  
(0.1) 



















21.11 (19.34–22.88) 0.090 
Total 223 44 93 133 145 449 30 8 1,080 18.73 (17.78–19.68) 0.001 




Most E30 VP1 sequences within clades G1, G2, G4, 
and G6 displayed specific amino acid substitutions. 
G6 sequences predominantly displayed amino acid 
changes at position 56 (Y-F), position 84 within the 
BC loop (V-A), position 87 within the BC loop (E-D), 
and position 145 (V/I) compared with G1, G2, and 
G4. Most G1 and G6 sequences had a valine at posi-
tions 54 and 120 compared with the G2 and G4 se-
quences, which had an isoleucine. At position 122, 
most G4 sequences contained a leucine, whereas G1, 
G2, and G6 sequences contained a phenylalanine. In-




We used 110 sequences containing both VP1 and 
3Dpol region and complete genome sequences to ana-
lyze recombination events between VP1 and the 3′ dis-
tal end of the E30 genome (Appendix Figure 1). The 
E30 3Dpol sequences formed a series of separate clus-
ters interspersed with those of other species B types, 
indicative of many within-species recombination 
events during their diversification (Figure 4). We took 
the entire published sequence dataset and used a 
nucleotide sequence distance threshold of 8%, based 
on pairwise sequence comparisons, which divided 
sequences into distinct groups (Appendix Figure 3), 
comparable to those derived from a previous analy-
sis of E30 RFs (17). Accordingly, species B could be 
divided into ≈442 RFs, an indication of the frequency 
and complexity of recombination events occurring 
during the evolution of this species. We used Next-
strain to generate an interactive tanglegram of VP1 
and 3Dpol RFs (https://nextstrain.org/community/
enterovirus-phylo/echo30-2019/3D:community/en-
terovirus-phylo/echo30-2019/vp1) (Figure 5).
We found that 3Dpol sequences of G1–G6 
formed 8 recombination groups, which were sep-
arated by other published E30 variants and by 
other species B types (Figure 5). We noted that vi-
ruses within most VP1 clades were monophyletic 
in 3Dpol, but that G1 and G4 each had undergone 
further recombination (Figure 5; Appendix Figure 
4), a split corresponding to the sublineages evident 
in the VP1-based tree. The split was identified as 
a time-related phenomenon, with G1 circulating in 
2018 representing a different RF from G1 circulat-
ing during 2016 and 2017.
Discussion
A large upsurge of E30 infections was reported 
in several countries in Europe during 2018 (2). We 
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Figure 3. Phylodynamic analysis of region 1 in a curated study of echovirus 30 (E30) viral protein 1 (VP1) sequences from 22 countries 
in Europe, 2010–2018. We constructed the bootstrapped maximum likelihood neighbor-joining trees using 47 full length sequences and 
277 VP1 sequences extracted from GenBank. E30 groups 1–8 are labeled. A) Maximum likelihood trees constructed by using MEGA 
version 7.0 (https://www.megasoftware.net). Prototype E30 strain Bastianni, (GenBank accession no. AF311938) was used  
as a reference. Scale bar indicates nucleotide substitutions per site. B) Maximum likelihood trees constructed by using Nextstrain 
(https://nextstrain.org) from which we dropped several problematic sequences, including group 5. 
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conducted a comprehensive molecular characteriza-
tion of E30 by using VP1, 3Dpol, and whole genome 
sequences. Our molecular characterization enabled an 
analysis of the recombination events occurring during 
E30 diversification in Europe, which can be conducted 
only when dealing with a single infection. Our study 
used a large EV sequence dataset collected worldwide, 
comprising 1,329 E30 sequences collected from 22 
countries in Europe during 2016–2018 and was made 
possible due to the large-scale collaboration between 
countries through ENPEN and ECDC.
The data clearly demonstrate that analysis based 
on phylogenetic clade assignment shows differential 
dominance of many different clades. The upsurge 
in 2018 was caused by appearance of several differ-
ent clades or genogroups of E30 viruses; G1 in GGII 
(7) and G6 in a novel genogroup, GGIII, which we 
propose in this study. Viruses from both clades had 
been circulating for >2 years. In total, 6 clades were 
identified during the study period and circulated in a 
pattern of rapid turnover of newly emerging genetic 
lineages and RFs and their relatively rapid disap-
pearance over time, a pattern that is typical for other 
enteroviruses (1,7,10,12,13,16–18,29). In this study, 
G2 predominated in 2016 and 2017 in central Europe 
and were subsequently replaced by the G1 and G6 
in 2018 (Figures 1, 2). This genetic turnover and the 
associated string of recombination events during lin-
eage diversification occurred within the 2- to 5-year 
cyclical pattern of E30 incidence. As expected, each 
VP1 group corresponded to a separate RF, but G1 un-
derwent a further recombination event as the virus 
diversified from a common ancestor dated to around 
2011 and G4 underwent a further recombination from 
an ancestor around 2008. Of note, clade G1 showed a 
time related split in which G1 sequences circulating 
in 2018 emerged from those circulating in 2016–2017, 
coinciding with a recombination generating a novel 
RF. The absence of G3 and G5 sequences in the study 
population might reflect a generally lower circula-
tion of these strains or perhaps a period of relative 
quiescence during the survey period. Long-term 
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Figure 4. Neighbor-joining 
tree of 3D polymerase (3Dpol) 
sequences of echovirus 30 (E30) 
study samples and sequences 
from previously described E30 
strains. The tree was constructed 
from Jukes-Cantor corrected 
nucleotide sequence distances 
in MEGA version 7.0 (https://
www.megasoftware.net). 
Colored circles represent clades 
G1–G6 from this study; black 
circles represent 581 previously 
described E30 strains; and 
unlabeled branches represent 
all other species B types (n = 
1,566) available in GenBank as 
of October 18, 2019. Scale bar 
indicates nucleotide substitutions 
per site.
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surveillance is essential to monitor for potential 
emergence of these strains in future incidence cycles.
The cocirculation of different E30 clades dur-
ing the 2018 upsurge and in previous years argues 
against the idea that the periodic emergence of E30 
occurs through the evolution of more pathogenic or 
transmissible forms of the virus. The cocirculation 
of several different groups fits better with changes 
in population susceptibility from birth cohort effects 
and a breach of a critical immunity level that controls 
E30 spread within the population (19). The high sus-
ceptibility is reflected by the high number of infected 
infants, who would have no immunity, and adults 
whom we hypothesize have no or waning immunity. 
However, another possibility is that the appearance of 
several, potentially convergent, amino acid substitu-
tions in VP1 among different E30 groups represented 
a form of antigenic selection for escape from existing 
population immunity. The clustering of sites under 
selection in the BC loop associated with receptor in-
teractions is consistent with this possibility. Serologic 
studies are required to explore this hypothesis.
As shown in the original description of the up-
surge (2), a high percentage of cases showed central 
nervous system involvement, particularly for infants 
0–3 months of age and adults 25–44 years of age, 
consistent with previous observations (2,30–32). The 
distribution of E30 clades varied among age groups; 
most infections in infants <3 months of age were 
caused by G1 and symptomatology varied from fe-
ver to acute flaccid paralysis. However, analysis of 
the clinical correlates was limited by incomplete re-
porting; only 30% of reported E30 infections included 
history of symptoms, which hampered comparisons 
of clinical presentation between different clades. An-
other limitation is the retrospective study design and 
bias toward severe and hospitalized cases.
Using Nextstrain, we visualized the various cat-
egories of demographic and clinical data, clades, and 
RFs. Unfortunately, G5 could not be inferred due to 
possible recombination events within the fragment. 
Complete reconstruction of E30 temporal events with 
geographic spread was hampered by the inevitably 
uneven sampling and testing in different years by the 
different contributing countries.
This study underpins the strength of the ENPEN 
consortium, which brings together virologists, public 
health experts, infectious disease doctors, and scien-
tists across Europe to enable rapid detection and early 
warning through standardized surveillance. Previ-
ous studies using Nextstrain with 2 EV-D68 datasets 
have shown the value of combining demographic and 
phylogenetic analysis, both as retrospective (33) and 
real-time analysis (34). The E30 dataset and the 2 EV-
D68 datasets (33,34) available on Nextstrain represent 
large nonpolio enterovirus datasets that support real-
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Figure 5. Tanglegram of echovirus 30 (E30) phylogenetic virus protein 1 (VP1) (right) and 3D polymerase (3Dpol) (left) by year of 
sample collection. We used 110 sequences and rendered the tanglegram by using Nextstrain (https://www.nextstrain.org). Clades G1–
G6 are labeled. 
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time tracking of viruses over time and across countries. 
These data are of considerable value in infection con-
tainment and control of nonpolio enteroviruses.
Differences in surveillance systems, case defini-
tions, and sample selection between institutes and 
countries make standardized data collection difficult, 
particularly for denominator data. The differences in 
data collection proved to be a limitation in our study, 
and the extent of the circulation of the different strains 
remains unknown. The emergence and disappearance 
of viruses from different clades across the years sug-
gests that some form of predictive modeling might be 
undertaken if data were standardized and provided in 
real-time through networks such as ENPEN. 
The mechanisms underlying the complex cyclic 
pattern of E30 and other enteroviruses and the effects 
of changing population immunity, antigenic changes, 
virus diversification, pathogenicity, and recombina-
tion need further exploration. The emergence of dif-
ferent enterovirus types, and their associated period-
icities and population penetrance, might be driven 
by multiple mechanisms (19), making outbreak and 
upsurge prediction complex. However, continued 
structured surveillance can clarify enterovirus circu-
lation and evolution and slowly aid in unraveling the 
complex nature of enteroviruses. 
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